These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31797922)

  • 1. Type I-F CRISPR-Cas resistance against virulent phages results in abortive infection and provides population-level immunity.
    Watson BNJ; Vercoe RB; Salmond GPC; Westra ER; Staals RHJ; Fineran PC
    Nat Commun; 2019 Dec; 10(1):5526. PubMed ID: 31797922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of Pectobacterium Bacteriophage ΦM1 To Escape Two Bifunctional Type III Toxin-Antitoxin and Abortive Infection Systems through Mutations in a Single Viral Gene.
    Blower TR; Chai R; Przybilski R; Chindhy S; Fang X; Kidman SE; Tan H; Luisi BF; Fineran PC; Salmond GPC
    Appl Environ Microbiol; 2017 Apr; 83(8):. PubMed ID: 28159786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abortive Infection: Bacterial Suicide as an Antiviral Immune Strategy.
    Lopatina A; Tal N; Sorek R
    Annu Rev Virol; 2020 Sep; 7(1):371-384. PubMed ID: 32559405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coevolution between bacterial CRISPR-Cas systems and their bacteriophages.
    Watson BNJ; Steens JA; Staals RHJ; Westra ER; van Houte S
    Cell Host Microbe; 2021 May; 29(5):715-725. PubMed ID: 33984274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas-Mediated Phage Resistance Enhances Horizontal Gene Transfer by Transduction.
    Watson BNJ; Staals RHJ; Fineran PC
    mBio; 2018 Feb; 9(1):. PubMed ID: 29440578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different genetic and morphological outcomes for phages targeted by single or multiple CRISPR-Cas spacers.
    Watson BNJ; Easingwood RA; Tong B; Wolf M; Salmond GPC; Staals RHJ; Bostina M; Fineran PC
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180090. PubMed ID: 30905290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CRISPRs go viral: The infection biology of CRISPR-Cas inhibitors.
    Li Y; Bondy-Denomy J
    Cell Host Microbe; 2021 May; 29(5):704-714. PubMed ID: 33444542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Type I-E and I-F CRISPR-Cas Systems in
    Xue C; Sashital DG
    EcoSal Plus; 2019 Feb; 8(2):. PubMed ID: 30724156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of temperate phages drives loss of type I CRISPR-Cas systems.
    Rollie C; Chevallereau A; Watson BNJ; Chyou TY; Fradet O; McLeod I; Fineran PC; Brown CM; Gandon S; Westra ER
    Nature; 2020 Feb; 578(7793):149-153. PubMed ID: 31969710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
    Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
    Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CRISPR Phages Cooperate to Overcome CRISPR-Cas Immunity.
    Landsberger M; Gandon S; Meaden S; Rollie C; Chevallereau A; Chabas H; Buckling A; Westra ER; van Houte S
    Cell; 2018 Aug; 174(4):908-916.e12. PubMed ID: 30033365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition.
    Dimitriu T; Kurilovich E; Łapińska U; Severinov K; Pagliara S; Szczelkun MD; Westra ER
    Cell Host Microbe; 2022 Jan; 30(1):31-40.e5. PubMed ID: 34932986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type III CRISPR-Cas provides resistance against nucleus-forming jumbo phages via abortive infection.
    Mayo-Muñoz D; Smith LM; Garcia-Doval C; Malone LM; Harding KR; Jackson SA; Hampton HG; Fagerlund RD; Gumy LF; Fineran PC
    Mol Cell; 2022 Dec; 82(23):4471-4486.e9. PubMed ID: 36395770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why put up with immunity when there is resistance: an excursion into the population and evolutionary dynamics of restriction-modification and CRISPR-Cas.
    Gurney J; Pleška M; Levin BR
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180096. PubMed ID: 30905282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phage-Encoded Anti-CRISPR Defenses.
    Stanley SY; Maxwell KL
    Annu Rev Genet; 2018 Nov; 52():445-464. PubMed ID: 30208287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The functional aspects of bacterial CRISPR-cas systems and interactions between phages and its bacterial hosts--a review].
    Fu Q; Sun J; Yan Y
    Wei Sheng Wu Xue Bao; 2015 Mar; 55(3):251-7. PubMed ID: 26065266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriophages suppress CRISPR-Cas immunity using RNA-based anti-CRISPRs.
    Camara-Wilpert S; Mayo-Muñoz D; Russel J; Fagerlund RD; Madsen JS; Fineran PC; Sørensen SJ; Pinilla-Redondo R
    Nature; 2023 Nov; 623(7987):601-607. PubMed ID: 37853129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How adaptive immunity constrains the composition and fate of large bacterial populations.
    Bonsma-Fisher M; Soutière D; Goyal S
    Proc Natl Acad Sci U S A; 2018 Aug; 115(32):E7462-E7468. PubMed ID: 30038015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages.
    Hynes AP; Villion M; Moineau S
    Nat Commun; 2014 Jul; 5():4399. PubMed ID: 25056268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phages Fight Back: Inactivation of the CRISPR-Cas Bacterial Immune System by Anti-CRISPR Proteins.
    Maxwell KL
    PLoS Pathog; 2016 Jan; 12(1):e1005282. PubMed ID: 26741979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.